AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18521048 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh (BC) treatment for 12 weeks at a standard dose (Remifemin, 40 mg/day)
Number of subjects: 11
Study 18521048 — intervention group
Group type: COMPARATOR
Intervention: Naloxone blockade
Number of subjects: 11
Study 18521048 — intervention group
Group type: COMPARATOR
Intervention: Naloxone blockade during sleep
Number of subjects: 11
Study 18521048 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh treatment
Number of subjects: 11
Study 16075684 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulator Vilon
Number of subjects: 0
Study 12219998 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT) using a frequency-doubled, Q-switched Nd:YAG laser (532 nm)
Number of subjects: 20
Study 12219998 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 20
Study 10519894 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation (myeloablative chemotherapy, total-body irradiation, and transplantation of autologous bone marrow)
Number of subjects: 379
Study 10519894 — intervention group
Group type: COMPARATOR
Intervention: Continuation chemotherapy (intensive chemotherapy alone)
Number of subjects: 379
Study 10519894 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (isotretinoin) for six months
Number of subjects: 379
Study 10519894 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 379
Study 8526187 — intervention group
Group type: COMPARATOR
Intervention: VAD (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 47
Study 8526187 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD plus interferon alfa-2
Number of subjects: 47
Study 8526187 — intervention group
Group type: COMPARATOR
Intervention: VAD
Number of subjects: 47
Study 8526187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VAD and VAD plus interferon)
Number of subjects: 47
Study 1760422 — intervention group
Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 59
Study 1760422 — intervention group
Group type: COMPARATOR
Intervention: IUI after ovarian hyperstimulation
Number of subjects: 59
Study 1760422 — intervention group
Group type: COMPARATOR
Intervention: IUI in a spontaneous cycle
Number of subjects: 59
Study 31442203 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea wilhelmsii C. Koch capsules
Number of subjects: 90
Study 31442203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 28650787 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% APF gel
Number of subjects: 60
Study 28650787 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP
Number of subjects: 60
Study 28650787 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 60
Study 26033094 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside Paediatric Early Warning System (BedsidePEWS)
Number of subjects: 0
Study 26033094 — intervention group
Group type: COMPARATOR
Intervention: Control (no severity of illness score)
Number of subjects: 0
Study 26033094 — intervention group
Group type: EXPERIMENTAL
Intervention: BedsidePEWS
Number of subjects: 0
Study 23811617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injection (40 mg of methylprednisolone)
Number of subjects: 46
Study 23811617 — intervention group
Group type: COMPARATOR
Intervention: Blind steroid injection (40 mg of methylprednisolone)
Number of subjects: 46
Study 21753226 — intervention group
Group type: EXPERIMENTAL
Intervention: dilute diesel exhaust
Number of subjects: 16
Study 21753226 — intervention group
Group type: EXPERIMENTAL
Intervention: pure carbon nanoparticulate
Number of subjects: 16
Study 21753226 — intervention group
Group type: EXPERIMENTAL
Intervention: filtered diesel exhaust
Number of subjects: 16
Study 21753226 — intervention group
Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 16
Study 19164401 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery during stretches (n = 6)
Number of subjects: 11
Study 19164401 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation during stretches (n = 5)
Number of subjects: 11
Study 17086095 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN), 60 mg orally, once daily for 11 months
Number of subjects: 47
Study 17086095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 14979844 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration health promotion projects (n = 728)
Number of subjects: 1955
Study 14979844 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 1,227)
Number of subjects: 1955
Study 11729017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 22
Study 11729017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9159453 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 27
Study 9159453 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor binding protein 1 (IGFBP-1)
Number of subjects: 27
Study 7970429 — intervention group
Group type: EXPERIMENTAL
Intervention: Two blood sample method
Number of subjects: 133
Study 7970429 — intervention group
Group type: COMPARATOR
Intervention: One blood sample method
Number of subjects: 133
Study 2444937 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional transvenous shocks (Group A)
Number of subjects: 33
Study 2444937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional transvenous shocks (Group B)
Number of subjects: 33
Study 31616139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortasyn Connect (daily medical food containing docosahexaenoic acid, eicosapentaenoic acid, uridine monophosphate, choline, phospholipids, selenium, folic acid, vitamins B12, B6, C, and E)
Number of subjects: 0
Study 31616139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortasyn Connect
Number of subjects: 0
Study 29045325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR) 25%
Number of subjects: 218
Study 29045325 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AL) control
Number of subjects: 218
Study 26112273 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) 12.5 μg/h
Number of subjects: 52
Study 26112273 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid anti-inflammatory drugs (NSAID)
Number of subjects: 52
Study 24108510 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (60 mg)
Number of subjects: 300
Study 24108510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 21784525 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter Valve
Number of subjects: 20
Study 21784525 — intervention group
Group type: COMPARATOR
Intervention: Control (normal ventilation in pressure controlled mode)
Number of subjects: 20
Study 19653757 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative spatial cues
Number of subjects: 0
Study 19653757 — intervention group
Group type: COMPARATOR
Intervention: Reflexive activation of location-sensitive neurons
Number of subjects: 0
Study 19653757 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory spatial cues
Number of subjects: 0
Study 16463435 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept/etanercept
Number of subjects: 141
Study 16463435 — intervention group
Group type: COMPARATOR
Intervention: placebo/etanercept
Number of subjects: 141
Study 12771841 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic decompression
Number of subjects: 38
Study 12771841 — intervention group
Group type: COMPARATOR
Intervention: Open decompression
Number of subjects: 38
Study 11016522 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified assertive community treatment
Number of subjects: 312
Study 11016522 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in community mental health centres
Number of subjects: 312
Study 9686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) alone
Number of subjects: 167
Study 9686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with sedation (midazolam: 1‐3 mg)
Number of subjects: 167
Study 9686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with general anaesthesia (patient's request)
Number of subjects: 167
Study 9686071 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (IBPB) with general anaesthesia (due to IBPB failure)
Number of subjects: 167
Study 8452378 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoured UHT cow's milk drink
Number of subjects: 169
Study 8452378 — intervention group
Group type: COMPARATOR
Intervention: Flavoured UHT soy milk drink (placebo)
Number of subjects: 169
Study 2943191 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg intramuscularly
Number of subjects: 96
Study 2943191 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (midazolam vehicle)
Number of subjects: 96
Study 29084094 — intervention group
Group type: EXPERIMENTAL
Intervention: LO + BFR group
Number of subjects: 25
Study 29084094 — intervention group
Group type: COMPARATOR
Intervention: HI group
Number of subjects: 25
Study 29084094 — intervention group
Group type: COMPARATOR
Intervention: LO group
Number of subjects: 25
Study 29145215 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 0
Study 29145215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26303694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 60
Study 26303694 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic surgery (TLS)
Number of subjects: 60
Study 23064733 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 340
Study 23064733 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP)
Number of subjects: 340
Study 21451458 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 21451458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19483355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100
Study 19483355 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 100
Study 16792771 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of salicylic acid (twice daily then once daily)
Number of subjects: 5
Study 16792771 — intervention group
Group type: COMPARATOR
Intervention: Control lesions (not treated with salicylic acid)
Number of subjects: 5
Study 15119640 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduate-measured volume using a 2-L graduated cylinder
Number of subjects: 28
Study 15119640 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighed volume, with and without bag weight, using a digital floor scale or spring scale
Number of subjects: 28
Study 15119640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycler-measured volume using the initial drain and ultrafiltration indicated by the cycler, plus the prescribed inflow volume without the last fill
Number of subjects: 28
Study 15119640 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight of the drained bags (for CAPD)
Number of subjects: 28
Study 11829239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile gloves
Number of subjects: 609
Study 11829239 — intervention group
Group type: COMPARATOR
Intervention: Clean gloves
Number of subjects: 609
Study 9517371 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (5 mg)
Number of subjects: 12
Study 9517371 — intervention group
Group type: EXPERIMENTAL
Intervention: nadolol (40 mg)
Number of subjects: 12
Study 9517371 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 7527104 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg
Number of subjects: 170
Study 7527104 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 1 mg
Number of subjects: 170
Study 7527104 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 170
Study 7527104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 2685740 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO) therapy
Number of subjects: 39
Study 2685740 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 39
Study 2685740 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival of ECMO-treated infants
Number of subjects: 39
Study 2685740 — intervention group
Group type: COMPARATOR
Intervention: Overall survival of CMT-treated infants
Number of subjects: 39
Study 1178099 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter shunts
Number of subjects: 260
Study 1178099 — intervention group
Group type: COMPARATOR
Intervention: Pudenz shunts
Number of subjects: 260
Study 29111629 — intervention group
Group type: EXPERIMENTAL
Intervention: Muay Thai training twice a week (G2X)
Number of subjects: 20
Study 29111629 — intervention group
Group type: EXPERIMENTAL
Intervention: Muay Thai training three times a week (G3X)
Number of subjects: 20
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a male vignette
Number of subjects: 483
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a female vignette
Number of subjects: 483
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants studying non-relevant degrees viewing a male vignette
Number of subjects: 483
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Students studying clinically non-relevant degrees
Number of subjects: 483
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MHFA scores
Number of subjects: 483
Study 26911725 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of support and information
Number of subjects: 483
Study 25803949 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Support Worker (PSW)
Number of subjects: 15
Study 25803949 — intervention group
Group type: COMPARATOR
Intervention: Mental Health Worker (MHW)
Number of subjects: 15
Study 22936289 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced respiration intervention
Number of subjects: 218
Study 22936289 — intervention group
Group type: COMPARATOR
Intervention: Fast shallow breathing control
Number of subjects: 218
Study 22936289 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 218
Study 20844186 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased leucine concentration (LEU; 3.5 g leucine)
Number of subjects: 14
Study 20844186 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL; 1.8 g leucine)
Number of subjects: 14
Study 19080342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Epithelial Keratomileusis (LASEK)
Number of subjects: 604
Study 19080342 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive Keratectomy (PRK)
Number of subjects: 604
Study 16844491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with controlled ovarian hyperstimulation for 6 months
Number of subjects: 253
Study 16844491 — intervention group
Group type: COMPARATOR
Intervention: Expectant management for 6 months
Number of subjects: 253
Study 12703999 — intervention group
Group type: EXPERIMENTAL
Intervention: PG regimen (cisplatin and gemcitabine)
Number of subjects: 64
Study 12703999 — intervention group
Group type: COMPARATOR
Intervention: PN regimen (cisplatin and vinorelbine)
Number of subjects: 64
Study 10954006 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 964
Study 10954006 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 964
Study 9368834 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) treatment
Number of subjects: 12
Study 1541712 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 27
Study 1541712 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 27
Study 3890465 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 27
Study 29799676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 40-500 mg QD
Number of subjects: 72
Study 29799676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 240-840 mg BID
Number of subjects: 72
Study 29799676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID (phase 2)
Number of subjects: 72
Study 29799676 — intervention group
Group type: COMPARATOR
Intervention: Rucaparib 40 mg (single dose)
Number of subjects: 72
Study 29799676 — intervention group
Group type: COMPARATOR
Intervention: Rucaparib 300 mg (single dose)
Number of subjects: 72
Study 29120980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-Water Immersion (CWI) for 20 minutes at 5-10° C
Number of subjects: 11
Study 29120980 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 11
Study 27936084 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (END) for 3 weeks (4 days/week) at ∼65% VO2peak work rate (30 minutes)
Number of subjects: 21
Study 27936084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training (SIT) for 3 weeks (4 days/week) with eight 20-second intervals at ∼170% VO2peak WR separated by 10 seconds of active rest
Number of subjects: 21
Study 27936084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both END and SIT
Number of subjects: 21
Study 25607702 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (2 treatments)
Number of subjects: 24
Study 25607702 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (1 treatment) + ingenol mebutate 0.015% gel (3 days)
Number of subjects: 24
Study 25607702 — intervention group
Group type: COMPARATOR
Intervention: ingenol mebutate 0.015% gel alone
Number of subjects: 24
Study 25607702 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (1 treatment) + ingenol mebutate gel (3 days)
Number of subjects: 24
Study 25607702 — intervention group
Group type: COMPARATOR
Intervention: ingenol mebutate gel alone
Number of subjects: 24
Study 23826844 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 3709
Study 23826844 — intervention group
Group type: COMPARATOR
Intervention: ER tolterodine 4 mg
Number of subjects: 3709
Study 23826844 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3709
Study 20642044 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft ice
Number of subjects: 32
Study 20642044 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced water
Number of subjects: 32
Study 20642044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice gel
Number of subjects: 32
Study 18521900 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective leukocytapheresis (5 sessions, once weekly)
Number of subjects: 60
Study 18521900 — intervention group
Group type: COMPARATOR
Intervention: Unchanged maintenance treatment (Control)
Number of subjects: 60
Study 18521900 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective leukocytapheresis
Number of subjects: 60
Study 15713151 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple tourniquets
Number of subjects: 28
Study 15713151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 12799510 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-9
Number of subjects: 262
Study 12799510 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (conjugate meningococcus C vaccine)
Number of subjects: 262
Study 11059992 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (single dose)
Number of subjects: 8
Study 11059992 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (six weeks treatment)
Number of subjects: 8
Study 8609218 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal fasting portal vein insulinemia-hypoglucagonemia
Number of subjects: 0
Study 8609218 — intervention group
Group type: COMPARATOR
Intervention: Basal portal vein insulinemia-basal glucagonemia
Number of subjects: 0
Study 8609218 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal peripheral insulinemia-hypoglucagonemia
Number of subjects: 0
Study 1616162 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 154
Study 1616162 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.02 mg/kg)
Number of subjects: 154
Study 1616162 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1.5 mg/kg)
Number of subjects: 154
Study 3745103 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, sublingual administration)
Number of subjects: 19
Study 3745103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Central obesity (WC > 80 cm for women and > 85 cm for men)
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MS) criteria
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Married/cohabit
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer working hours
Number of subjects: 737
Study 29067841 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating less vegetables
Number of subjects: 737
Study 26679060 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HFrTMS (10 Hz, 100% motor threshold)
Number of subjects: 17
Study 26679060 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 17
Study 24879495 — intervention group
Group type: COMPARATOR
Intervention: THC 29 mg
Number of subjects: 24
Study 24879495 — intervention group
Group type: COMPARATOR
Intervention: THC 49 mg
Number of subjects: 24
Study 24879495 — intervention group
Group type: COMPARATOR
Intervention: THC 69 mg
Number of subjects: 24
Study 24879495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23039319 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose amoxicillin/clavulanic acid (80 mg/kg/day for 10 days)
Number of subjects: 330